E cone gas was set to 50 L/h and the ion source temperature at 120 . The instrument was operated in W mode with a resolution greater than ten.000. Data had been obtained in centroid mode from m/z 50 to 1000 working with a acquisition price of 1 s/scan. The extracted-ionBeilstein J. Org. Chem. 2014, 10, 1339?346.give a clear luciferase signal within the linear range at day three post-infection. Infectivity was measured in triplicate and reported because the percentage of luciferase activity in comparison with the luciferase activity corresponding to the wells with virus and no drug. The concentration of drug necessary to inhibit 50 with the viral infectivity (IC50) was determined.11. Lisziewicz, J.; Tke, E. R. Nanomed. Nanotechnol. Biol. Med. 2013, 9, 28?8. doi:10.1016/j.nano.2012.05.012 12. Boisselier, E.; Astruc, D. Chem. Soc. Rev. 2009, 38, 1759?782. doi:10.1039/b806051g 13. Dykman, L.; Khlebtsov, N. Chem. Soc. Rev. 2012, 41, 2256?282. doi:10.1039/c1cs15166e 14. Duncan, B.; Kim, C.; Rotello, V. M. J. Controlled Release 2010, 148, 122?27. doi:10.1016/j.jconrel.2010.06.004 15. Bowman, M.-C.; Ballard, T. E.; Ackerson, C. J.; Feldheim, D. L.;Supporting InformationSupporting Information FileSynthesis and characterization of thiol-ending prodrugs and GNPs; HPLC S chromatograms, mass spectra and drugs calibration curves; calculation of drug-loading on GNPs. [http://beilstein-journals.org/bjoc/content/ supplementary/1860-5397-10-136-S1.pdf]Margolis, D. M.; Melander, C. J. Am. Chem. Soc. 2008, 130, 6896?897. doi:ten.1021/ja710321g 16. Elechiguerra, J. L.; Burt, J. L.; Morones, J. R.; Camacho-Bragado, A.; Gao, X.; Lara, H. H.; Yacaman, M. J. J. NanoBiotechnology 2005, three, No. 6. doi:10.1186/1477-3155-3-6 17. Shiang, Y.-C.; Ou, C.-M.; Chen, S.-J.; Ou, T.-Y.; Lin, H.-J.; Huang, C.-C.; Chang, H.-T. Nanoscale 2013, 5, 2756?764. doi:ten.1039/c3nr33403a 18. Di Gianvincenzo, P.; Chiodo, F.; Marradi, M.; Penad , S. Solutions Enzymol. 2012, 509, 21?0. doi:10.1016/B978-0-12-391858-1.00002-AcknowledgementsWe thank Dr. Miguel gel von Wichmann from Hospital Donostia (San Sebasti ) for his suggestions and scientific support. Financial help from the EU (grant CHAARM), the MINECO (grant No. CTQ2011-27268) plus the Division of Industry with the Basque Nation (Grant No.5-Cyclopropyl-1H-imidazole Purity ETORTEK2011) is acknowledged. F.Buy2-Chloro-5-sulfamoylbenzoic acid C.PMID:33618591 was supported by the Spanish Ministry of Science and Innovation, MICINN (Grant No. CTQ200804638). M.M. and S.P. acknowledge EU Cost Action CM1102.19. Mart ez- ila, O.; Bedoya, L. M.; Marradi, M.; Clavel, C.; Alcam? J.; Penad , S. ChemBioChem 2009, ten, 1806?809. doi:10.1002/cbic.200900294 20. Di Gianvincenzo, P.; Marradi, M.; Mart ez- ila, O.; Bedoya, L. M.; Alcam? J.; Penad , S. Bioorg. Med. Chem. Lett. 2010, 20, 2718?721. doi:10.1016/j.bmcl.2010.03.079 21. Marradi, M.; Chiodo, F.; Garc , I.; Penad , S. Chem. Soc. Rev. 2013, 42, 4728?745. doi:10.1039/c2cs35420a 22. Arn z, B.; Mart ez- ila, O.; Falcon-Perez, J. M.; Penad , S. Bioconjugate Chem. 2012, 23, 814?25. doi:ten.1021/bc200663r 23. de la Fuente, J. M.; Alc tara, D.; Penad , S. IEEE Trans. Nanobiosci. 2007, six, 275?81. doi:ten.1109/TNB.2007.908981 24. Irure, A.; Marradi, M.; Arn z, B.; Genicio, N.; Padro, D.; Penad , S. Biomater. Sci. 2013, 1, 658?68. doi:ten.1039/c3bm60032g 25. Murray, R. A.; Qiu, Y.; Chiodo, F.; Marradi, M.; Penad , S.; Moya, S. E. Little 2014. doi:ten.1002/smll.201303604 26. Moros, M.; Hern z, B.; Garet, E.; Dias, J. T.; S z, B.; Graz? V.; Gonz ez-Fern dez, A.; Alonso, C.; de la Fuente, J. M. ACS Nano 2012, six, 1565?577. doi:.
